Update on hepatitis C virus resistance to direct-acting antiviral agents [PDF]
, 2014 Review[Abstract] Resistance to direct-acting antiviral (DAA) agents against hepatitis C virus (HCV) infection is driven by the selection of mutations at different positions in the NS3 protease, NS5B polymerase and NS5A proteins.
Cachay, Edward +5 more
core +2 more sources
Chinese Medical Journal, 2015 Background: It has been reported that several baseline polymorphisms of direct-acting antivirals (DAAs) agents resistance-associated variants (RAVs) would affect the treatment outcomes of patients chronically infected with hepatitis C virus (CHC).
Ye Wang +3 more
doaj +1 more source
PLoS ONE, 2015 BackgroundHepatitis C virus (HCV) infection is one of the major causes of cirrhosis and hepatocellular carcinoma. HCV nonstructural protein 5A (NS5A) is an attractive antiviral target and plays an important role in HCV replication as well as ...
Xia Jiang +9 more
doaj +1 more source
Effectiveness and safety of sofosbuvir‐based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis: results of a multicenter real‐life cohort [PDF]
, 2016 [Abstract] Patients with HCV genotype 3 (GT3) infection and cirrhosis are currently the most difficult to cure. We report our experience with sofosbuvir+daclatasvir (SOF+DCV) or sofosbuvir/ledipasvir (SOF/LDV), with or without ribavirin (RBV) in clinical
Alonso, S. +27 more
core +2 more sources
Recent advances in managing chronic HCV infection: Focus on therapy in patients with severe liver disease [PDF]
, 2016 Chronic hepatitis C virus (HCV) infection still represents a major public health problem, as it is thought to be responsible for more than 350,000 deaths around the globe on a yearly basis.
Maan, R. (Raoel) +1 more
core +5 more sources
Hepatitis C virus NS5A targets the nucleosome assembly protein NAP1L1 to control the innate cellular response [PDF]
, 2017 Hepatitis C virus (HCV) is a single-stranded positive-sense RNA hepatotropic virus. Despite cellular defenses, HCV is able to replicate in hepatocytes and to establish a chronic infection that could lead to severe complications and hepatocellular ...
Cesarec, Mia +5 more
core +1 more source
Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications [PDF]
, 2015 One-fourth of individuals diagnosed with the human immunodeficiency virus concomitantly have the hepatitis C virus infection. Since the discovery of highly active antiretroviral therapy, liver complications have become the leading cause of morbidity and ...
Gandhi, Mona A. +2 more
core +2 more sources
Hepatitis C virus NS5A inhibitors and drug resistance mutations
World Journal of Gastroenterology, 2014 Some direct-acting antiviral agents for hepatitis C virus (HCV), such as telaprevir and boceprevir have been available since 2011. It was reported that HCV NS5A is associated with interferon signaling related to HCV replication and hepatocarcinogenesis. HCV NS5A inhibitors efficiently inhibited HCV replication in vitro.
Shingo, Nakamoto +4 more
openaire +2 more sources
Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors [PDF]
Antimicrobial Agents and Chemotherapy, 2017 ABSTRACT Hepatitis C virus (HCV) strains belong to seven genotypes with numerous subtypes that respond differently to antiviral therapies. Genotype 1, and primarily subtype 1b, is the most prevalent genotype worldwide. The development of recombinant HCV infectious cell culture systems for different variants, permitted by the high
Pham, Long V. +5 more
openaire +3 more sources
Modulation of triglyceride and cholesterol ester synthesis impairs assembly of infectious hepatitis C virus [PDF]
, 2014 In hepatitis C virus infection, replication of the viral genome and virion assembly are linked to cellular metabolic processes. In particular, lipid droplets, which store principally triacylglycerides (TAGs) and cholesterol esters (CEs), have been ...
Hague, Charlotte V. +4 more
core +1 more source